The Rise and Limits of Weight Loss Medications Powerful new weight management drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide, have significantly changed how obesity is treated
PLOS ONE 12, e0169761
All case series and reports 151,152,153,154,155 reported better metabolic outcomes in patients with comorbid severe mental illness and diabetes and/or obesity who were concomitantly treated with antipsychotics and GLP-1RAs
All patients were overweight with a mean body mass index of 35.6 (range 3537) and have been using semaglutide for weight loss for a mean duration of 11.3 weeks (range 616)
While tirzepatide uses GIP to enhance insulin sensitivity and metabolic efficiency, retatrutide adds direct fat-burning stimulation through glucagon
Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, SGLT-2i, and GLP-1 receptor agonists